ARTICLE | Company News
Astellas, Immunomics enter $300M allergy vaccine deal
October 10, 2015 1:32 AM UTC
Immunomic Therapeutics Inc. (Hershey, Pa.) granted Astellas Pharma Inc. (Tokyo:4503) exclusive, worldwide rights to develop and commercialize candidates derived from its LAMP-vax platform to treat or prevent allergic diseases. Astellas gained an exclusive option to negotiate the license under a January deal.
Immunomic will receive $300 million up front plus 10% royalties on LAMP-vax products for allergic diseases. It will retain rights to LAMP-vax for other applications, including cancer immunotherapy. ...